← Back to Clinical Trials
Recruiting NCT05490901

NCT05490901 The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05490901
Status Recruiting
Phase
Sponsor Samsung Medical Center
Condition Heart Failure With Preserved Ejection Fraction
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2020-03-17
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Exercise hemodynamic test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2020-03-17 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the role of exercise hemodynamic testing in the diagnostic workup for patients with dyspnea on exertion referred to the catheterization lab.

Eligibility Criteria

Inclusion Criteria: * Subject must be at least 19 years of age. * Patients with dyspnea on exertion * Written informed consent of participating subjects after being fully briefed (for prospective analysis) Exclusion Criteria: * Patients with incomplete hemodynamic data at rest or exercise * Advanced tumor disease or other diseases with a short life expectancy * Uncontrolled systemic arterial hypertension ( \> 160/100 mmHg at rest) * FEV1\<50% predicted * TLC\<60% predicted

Contact & Investigator

Central Contact

Jeong Hoon Yang, MD

✉ jhysmc@gmail.com

📞 82-2-3410-3419

Principal Investigator

Jeong Hoon Yang, MD

PRINCIPAL INVESTIGATOR

Samsung Medical Center

Frequently Asked Questions

Who can join the NCT05490901 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Heart Failure With Preserved Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05490901 currently recruiting?

Yes, NCT05490901 is actively recruiting participants. Contact the research team at jhysmc@gmail.com for enrollment information.

Where is the NCT05490901 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT05490901 clinical trial?

NCT05490901 is sponsored by Samsung Medical Center. The principal investigator is Jeong Hoon Yang, MD at Samsung Medical Center. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology